Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ENTERPRET: A Randomized Controlled Trial of Vedolizumab Dose Optimization in Patients With Ulcerative Colitis Who Have Early Nonresponse.
Jairath V, Yarur A, Osterman MT, James A, Balma D, Mehrotra S, Yang L, Yajnik V, Qasim Khan RM. Jairath V, et al. Among authors: yarur a. Clin Gastroenterol Hepatol. 2024 May;22(5):1077-1086.e13. doi: 10.1016/j.cgh.2023.10.029. Epub 2023 Nov 10. Clin Gastroenterol Hepatol. 2024. PMID: 37951560 Free article. Clinical Trial.
Achievement of clinical, endoscopic, and histologic outcomes in patients with ulcerative colitis treated with etrasimod, and association with fecal calprotectin and C-reactive protein: results from the Phase 2 OASIS trial.
Yarur AJ, Chiorean MV, Panés J, Jairath V, Zhang J, Rabbat CJ, Sandborn WJ, Vermeire S, Peyrin-Biroulet L. Yarur AJ, et al. J Crohns Colitis. 2024 Jan 20:jjae007. doi: 10.1093/ecco-jcc/jjae007. Online ahead of print. J Crohns Colitis. 2024. PMID: 38245818
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
Sandborn WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, Panes J, Yarur A, Ritter T, Baert F, Schreiber S, Sloan S, Cataldi F, Shan K, Rabbat CJ, Chiorean M, Wolf DC, Sands BE, D'Haens G, Danese S, Goetsch M, Feagan BG. Sandborn WJ, et al. Among authors: yarur a. Lancet. 2023 Apr 8;401(10383):1159-1171. doi: 10.1016/S0140-6736(23)00061-2. Epub 2023 Mar 2. Lancet. 2023. PMID: 36871574 Free article. Clinical Trial.
Reply.
Yarur AJ, Deepak P. Yarur AJ, et al. Gastroenterology. 2024 Feb;166(2):357-358. doi: 10.1053/j.gastro.2023.11.013. Epub 2023 Nov 11. Gastroenterology. 2024. PMID: 37952900 No abstract available.
The Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study.
Verstockt B, Vermeire S, Peyrin-Biroulet L, Mosig R, Feagan BG, Colombel JF, Siegmund B, Rieder F, Schreiber S, Yarur A, Panaccione R, Dubinsky M, Lichtiger S, Cataldi F, Danese S. Verstockt B, et al. Among authors: yarur a. J Crohns Colitis. 2023 Nov 11:jjad192. doi: 10.1093/ecco-jcc/jjad192. Online ahead of print. J Crohns Colitis. 2023. PMID: 37952114
Comparative Persistence of Non-tumor Necrosis Factor (TNF) vs. TNF Antagonists for Post-operative Prophylaxis in Crohn's Disease (CD).
Gu P, Dube S, Lee Y, Yang S, Li D, Haritunians T, Vasiliauskas E, Bonthala N, Syal G, Yarur A, Ziring D, Targan S, Rabizadeh S, Melmed GY, Fleshner P, McGovern DPB. Gu P, et al. Among authors: yarur a. Dig Dis Sci. 2024 Jan;69(1):235-245. doi: 10.1007/s10620-023-08192-w. Epub 2023 Nov 28. Dig Dis Sci. 2024. PMID: 38015321 Free PMC article.
Pre-operative visceral adipose tissue radiodensity is a potentially novel prognostic biomarker for early endoscopic post-operative recurrence in Crohn's disease.
Gu P, Dube S, Gellada N, Choi SY, Win S, Lee YJ, Yang S, Haritunians T, Melmed GY, Vasiliauskas EA, Bonthala N, Syal G, Yarur AJ, Ziring D, Rabizadeh S, Fleshner P, Kallman C, Devkota S, Targan SR, Li D, McGovern DP. Gu P, et al. Among authors: yarur aj. World J Gastrointest Surg. 2024 Mar 27;16(3):740-750. doi: 10.4240/wjgs.v16.i3.740. World J Gastrointest Surg. 2024. PMID: 38577075 Free PMC article.
91 results